Antibody based therapy for childhood solid cancers

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Current opinion in chemical engineering

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.COCHE.2018.01.005
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Olaratumab for soft tissue sarcoma

  2017cited by this paper
• Phase 1/2 Study of the CD56‐Targeting Antibody‐Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small‐Cell Lung Cancer Patients With Extensive‐Stage Disease

  2017cited by this paper
• TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data.

  2017cited by this paper
• Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy

  2017cited by this paper
• Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review

  2017cited by this paper
• Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

  2017cited by this paper
• Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

  2017cited by this paper
• Monoclonal Antibodies for the Treatment of Cancer.

  2017cited by this paper
• Denosumab: an Emerging Therapy in Pediatric Bone Disorders

  2017cited by this paper
• Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

  2016cited by this paper
• Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors

  2016cited by this paper
• Antibody-drug conjugates—an emerging class of cancer treatment

  2016cited by this paper
• Harnessing Fc receptor biology in the design of therapeutic antibodies.

  2016cited by this paper
• Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

  2016cited by this paper
• Targeting Glycoprotein NMB With Antibody‐Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

  2016cited by this paper
• EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.

  2015cited by this paper
• Phase I trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A Children’s Oncology Group Study.

  2015cited by this paper
• A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study.

  2015cited by this paper
• Comparison of pain outcomes between two anti‐GD2 antibodies in patients with neuroblastoma

  2015cited by this paper
• Mechanisms of action of therapeutic antibodies for cancer.

  2015cited by this paper
• Disialoganglioside GD2 as a therapeutic target for human diseases

  2015cited by this paper
• Alternative molecular formats and therapeutic applications for bispecific antibodies.

  2015cited by this paper
• T cell exclusion, immune privilege, and the tumor microenvironment

  2015cited by this paper
• Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

  2015cited by this paper
• Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia

  2014cited by this paper
• Antibody-drug conjugates: current status and future directions.

  2014cited by this paper
• Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.

  2014cited by this paper
• Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood

  2014cited by this paper
• Anti-angiogenic therapy in pediatric brain tumors: an effective strategy?

  2014cited by this paper
• Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma.

  2013cited by this paper
• Treatment of children with high grade glioma with nimotuzumab: A 5-y institutional experience

  2013cited by this paper
• Cell cycle arrest and apoptosis induced by O-acetyl-GD2-specific monoclonal antibody 8B6 inhibits tumor growth in vitro and in vivo.

  2013cited by this paper
• Targeting the insulin-like growth factor-1 receptor in human cancer

  2013cited by this paper
• Monoclonal TCR-redirected tumor cell killing

  2012cited by this paper
• Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group.

  2012cited by this paper
• Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

  2012cited by this paper
• Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.

  2012cited by this paper
• Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.

  2012cited by this paper
• Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

  2011cited by this paper
• R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study.

  2011cited by this paper
• HER2: biology, detection, and clinical implications.

  2011cited by this paper
• A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity

  2011cited by this paper
• First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

  2010cited by this paper
• Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

  2010cited by this paper
• Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma

  2010cited by this paper
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

  2010cited by this paper
• Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

  2010cited by this paper
• Anti‐GD2 with an FC point mutation reduces complement fixation and decreases antibody‐induced allodynia

  2010cited by this paper
• The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.

  2009cited by this paper
• B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interaction

  2009cited by this paper
• The cancer genome

  2009cited by this paper
• Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration

  2007cited by this paper
• PDGF receptors as targets in tumor treatment.

  2007cited by this paper
• FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor.

  2006cited by this paper
• Pediatric Cancers Are Infiltrated Predominantly by Macrophages and Contain a Paucity of Dendritic Cells: a Major Nosologic Difference with Adult Tumors

  2006cited by this paper
• Engineered antibody fragments and the rise of single domains

  2005cited by this paper
• Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2-a preliminary report

  2005cited by this paper
• Childhood solid tumours: a developmental disorder

  2005cited by this paper
• Inflammation and necrosis promote tumour growth

  2004cited by this paper
• Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation.

  2000cited by this paper
• Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.

  1999cited by this paper
• T cell major histocompatibility complex class II molecules down‐regulate CD4+ T cell clone responses following LAG‐3 binding

  1996cited by this paper
• Disialoganglioside GD2 in human neuroectodermal tumor cell lines and gliomas

  1991cited by this paper
• Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.

  1987cited by this paper
• Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.

  1986cited by this paper

• No citing papers are available for this paper.